Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinomaMakoto Nishino, Tomoko Betsuyaku|Journal of Cancer|2017Cited by 37
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Masayoshi Miyawaki, Kenzo Soejima, Aoi Kuroda et al.|Molecular and Clinical Oncology|2017Cited by 10
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancerKenzo Soejima, Tomoko Betsuyaku, Katsuhiko Naoki et al.|Cancer Chemotherapy and Pharmacology|2015Cited by 7
Abstract 3006: Hyperoxia may be a treatment option for NSCLCJunko Hamamoto, Kenzo Soejima, Hiroyuki Yasuda et al.|Cancer Research|2015Cited by 0
A phase II trial of induction Erlotinib followed by chemotherapy with Platinum + Pemetrexed +/- Bevacizumab for EGFR mutation-positive non-squamous non-small cell lung cancer patients.Tetsuo Tani, Tomoko Betsuyaku, Kenzo Soejima et al.|Journal of Clinical Oncology|2015Cited by 0